202857-89-4 Usage
Description
2-(Benzyloxy)-4-fluorobenzaldehyde is an organic compound characterized by the presence of a benzyloxy group attached to the 2-position and a fluorine atom at the 4-position of a benzene ring. It features an aldehyde functional group, which makes it a versatile intermediate in organic synthesis.
Uses
Used in Pharmaceutical Industry:
2-(Benzyloxy)-4-fluorobenzaldehyde is used as a reactant for the synthesis of fluorinated hallucinogenic tryptamine derivatives. These compounds are of interest in the development of new psychoactive substances and potential therapeutic agents for various neurological and psychiatric disorders.
Used in Organic Synthesis:
Due to its unique structure and functional groups, 2-(Benzyloxy)-4-fluorobenzaldehyde can be employed as a building block in the synthesis of a wide range of organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its reactivity and selectivity in various chemical reactions make it a valuable component in the development of new synthetic routes and methodologies.
Check Digit Verification of cas no
The CAS Registry Mumber 202857-89-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,8,5 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 202857-89:
(8*2)+(7*0)+(6*2)+(5*8)+(4*5)+(3*7)+(2*8)+(1*9)=134
134 % 10 = 4
So 202857-89-4 is a valid CAS Registry Number.
202857-89-4Relevant articles and documents
Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound
-
Paragraph 0420-0424, (2020/12/01)
The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.
COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE
-
Paragraph 0058, (2016/01/25)
Provided herein are compounds of Formula (I), or a stereoisomer, a geometric isomer, an enantiomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which are used in the treatment of HCV
N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS
-
Page/Page column 64-65, (2010/11/04)
Disclosed herein are substantially pure forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, stereoisomer or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.
